Amanote Research
Register
Sign In
Understanding Hyperprogression in Cancer
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nd2019-003
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
April 25, 2019
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
The Good, the Bad, and the Ugly: Hyperprogression in Cancer Patients Following Immune Checkpoint Therapy
Genome Medicine
Molecular Medicine
Genetics
Molecular Biology
P3.01-56 Hyperprogression and Pseudoprogression in Patients With Non-Small Cell Lung Cancer on Checkpoint Blocking Immunotherapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Understanding the Bone in Cancer Metastasis
Journal of Bone and Mineral Research
Endocrinology
Orthopedics
Sports Medicine
Metabolism
Diabetes
Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-Junction Adenocarcinoma After Pembrolizumab
Cureus
Understanding Cancer-Induced Cachexia
Current Opinion in Supportive and Palliative Care
Medicine
Oncology
Critical Care
Intensive Care Medicine
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Trends in Cancer
Cancer Research
Oncology
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Oncologist
Cancer Research
Medicine
Oncology
Understanding Prostate Cancer in African-American Men
Cancer Discovery
Oncology
Understanding Taste Dysfunction in Patients With Cancer
Clinical Journal of Oncology Nursing
Oncology